Bangalore N, Drohan W N, Orthner C L
Plasma Derivatives Laboratory, American Red Cross Holland Laboratory, Rockville, Maryland 20855.
Thromb Haemost. 1994 Sep;72(3):465-74.
Activated protein C (APC) is an antithrombotic serine proteinase having anticoagulant, profibrinolytic and anti-inflammatory activities. Despite its potential clinical utility, relatively little is known about its clearance mechanisms. In the present study we have characterized the interaction of APC and its active site blocked forms with human umbilical vein endothelial cells (HUVEC). At 4 degrees C 125I-APC bound to HUVEC in a specific, time dependent, saturable and reversible manner. Scatchard analysis of the binding isotherm demonstrated a Kd value of 6.8 nM and total number of binding sites per cell of 359,000. Similar binding isotherms were obtained using radiolabeled protein C (PC) zymogen as well as D-phe-pro-arg-chloromethylketone (PPACK) inhibited APC indicating that a functional active site was not required. Competition studies showed that the binding of APC, PPACK-APC and PC were mutually exclusive suggesting that they bound to the same site(s). Proteolytic removal of the N-terminal gamma-carboxyglutamic acid (gla) domain of PC abolished its ability to compete indicating that the gla-domain was essential for cell binding. Surprisingly, APC binding to these cells appeared to be independent of protein S, a cofactor of APC generally thought to be required for its high affinity binding to cell surfaces. The identity of the cell binding site(s), for the most part, appeared to be distinct from other known APC ligands which are associated with cell membranes or extracellular matrix including phospholipid, thrombomodulin, factor V, plasminogen activator inhibitor type 1 (PAI-1) and heparin. Pretreatment of HUVEC with antifactor VIII antibody caused partial inhibition of 125I-APC binding indicating that factor VIII or a homolog accounted for approximately 30% of APC binding. Studies of the properties of surface bound 125I-APC or 125I-PC and their fate at 4 degrees C compared to 37 degrees C were consistent with association of approximately 25% of the initially bound radioligand with an endocytic receptor. However, most of the radioligand appeared not to be bound to an endocytic receptor and dissociated rapidly at 37 degrees C in an intact and functional state. These data indicate the presence of specific, high affinity binding sites for APC and PC on the surface of HUVEC. While a minor proportion of binding sites may be involved in endocytosis, the identity and function of the major proportion is presently unknown. It is speculated that this putative receptor may be a further mechanisms of localizing the PC antithrombitic system to the vascular endothelium.
活化蛋白C(APC)是一种具有抗血栓形成作用的丝氨酸蛋白酶,具有抗凝、促纤溶和抗炎活性。尽管其具有潜在的临床应用价值,但对其清除机制的了解相对较少。在本研究中,我们对APC及其活性位点被封闭的形式与人脐静脉内皮细胞(HUVEC)的相互作用进行了表征。在4℃下,125I-APC以特异性、时间依赖性、可饱和且可逆的方式与HUVEC结合。对结合等温线进行Scatchard分析显示,解离常数(Kd)值为6.8 nM,每个细胞的结合位点总数为359,000个。使用放射性标记的蛋白C(PC)酶原以及D-苯丙氨酸-脯氨酸-精氨酸-氯甲基酮(PPACK)抑制的APC获得了相似的结合等温线,这表明功能性活性位点并非必需。竞争研究表明,APC、PPACK-APC和PC的结合相互排斥,这表明它们结合到相同的位点。对PC的N端γ-羧基谷氨酸(gla)结构域进行蛋白水解去除后,其竞争能力丧失,这表明gla结构域对于细胞结合至关重要。令人惊讶的是,APC与这些细胞的结合似乎独立于蛋白S,蛋白S是APC的一种辅助因子,通常认为它是APC与细胞表面高亲和力结合所必需的。在很大程度上,细胞结合位点的身份似乎与其他已知的与细胞膜或细胞外基质相关的APC配体不同,这些配体包括磷脂、血栓调节蛋白、因子V、纤溶酶原激活物抑制剂1型(PAI-1)和肝素。用抗因子VIII抗体预处理HUVEC会导致125I-APC结合部分受到抑制,这表明因子VIII或其同源物约占APC结合的30%。与37℃相比,对表面结合的125I-APC或125I-PC的性质及其在4℃下的命运进行的研究表明,约25%的初始结合放射性配体与内吞受体相关。然而,大多数放射性配体似乎并未与内吞受体结合,而是在37℃下以完整且有功能的状态迅速解离。这些数据表明HUVEC表面存在针对APC和PC的特异性、高亲和力结合位点。虽然一小部分结合位点可能参与内吞作用,但大部分结合位点的身份和功能目前尚不清楚。据推测,这种假定的受体可能是将PC抗血栓系统定位于血管内皮的另一种机制。